Oral anti-CD3 MAb Immunization / Immunotherapy – Clinical proof of principle
Dr Ronald Ellis, Senior Vice President, Research & Development and Chief Technology Officer, NasVax joined us at the World Vaccine Congress Lyon 2012 to give a presentation on the clinical proof of principle of Oral anti-CD3 MAb Immunization/Immunotherapy. With focus on the following, this presentation provides all the information you need to find out more about the use of Oral anti-CD3 MAb Immunization / Immunotherapy:
- Oral anti-CD3 MAb immunization – Clinical proof of principle
- Oral administration results in the induction of regulatory T cells for alleviating inflammatory and autoimmune diseases with excellent safety
- Phase 2a clinical study in subjects with NASH (fatty liver disease) and altered glucose metabolism (some with T2D) showed favourable changes in clinical biomarkers for hepatitis and glucose metabolism
- First monoclonal antibody administered by oral route in clinical trials.